<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055757</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02808</org_study_id>
    <secondary_id>MC0123</secondary_id>
    <secondary_id>N01CM17104</secondary_id>
    <secondary_id>N01CM17102</secondary_id>
    <nct_id>NCT00055757</nct_id>
  </id_info>
  <brief_title>Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Trial of R115777, a Farnesyl Transferase Inhibitor, in Combination With Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of combining tipifarnib with gemcitabine and&#xD;
      cisplatin in treating patients who have stage III or stage IV non-small cell lung cancer.&#xD;
      Drugs used in chemotherapy such as gemcitabine and cisplatin use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Tipifarnib may stop the growth of tumor&#xD;
      cells by blocking the enzymes necessary for tumor cell growth. Combining tipifarnib with&#xD;
      combination chemotherapy may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the response rate in non-small cell lung cancer (NSCLC) patients receiving&#xD;
      combination therapy with R115777, gemcitabine, and cisplatin.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the time to event efficacy variables including: time to progressive disease,&#xD;
      time to treatment failure, time to death of any cause.&#xD;
&#xD;
      II. To estimate the duration of response for responding patients. III. To characterize the&#xD;
      toxicities of R115777, gemcitabine, and cisplatin in this patient population.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the association between polymorphism expression in candidate genes and&#xD;
      clinical endpoints and toxicity to R115777, gemcitabine, and cisplatin.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on&#xD;
      days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up&#xD;
      to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with at least stable disease may continue to receive oral tipifarnib alone twice&#xD;
      daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart</measure>
    <time_frame>Up to 18 weeks (6 courses)</time_frame>
    <description>Ninety-five percent confidence intervals for the true success proportion will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>Time from registration to death due to any cause, assessed up to 2 years</time_frame>
    <description>The distribution of survival time will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Time from registration to documentation of disease progression, assessed up to 2 years</time_frame>
    <description>The distribution of time to progression will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (tipifarnib, gemcitabine, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (tipifarnib, gemcitabine, cisplatin)</arm_group_label>
    <other_name>R115777</other_name>
    <other_name>Zarnestra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tipifarnib, gemcitabine, cisplatin)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tipifarnib, gemcitabine, cisplatin)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tipifarnib, gemcitabine, cisplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed NSCLC with one of the following classifications:&#xD;
&#xD;
               -  Stage IIIB with pleural effusion&#xD;
&#xD;
               -  Stage IIIB and not a candidate for combined modality treatment with radiation&#xD;
                  therapy and chemotherapy&#xD;
&#xD;
               -  Stage IV&#xD;
&#xD;
          -  Measurable disease, defined as at least one lesion whose longest diameter can be&#xD;
             accurately measured as &gt;= 2.0 cm&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3&#xD;
&#xD;
          -  PLT &gt;= 100,000&#xD;
&#xD;
          -  Hgb &gt; 10.0 g/dL&#xD;
&#xD;
          -  Direct bilirubin =&lt; 1.5 x UNL&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 5 x UNL&#xD;
&#xD;
          -  AST =&lt; 3 x UNL&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x UNL&#xD;
&#xD;
          -  ECOG Performance Status (PS) 0 or 1&#xD;
&#xD;
          -  Capable of understanding the investigational nature, potential risks and benefits of&#xD;
             the study and able to provide valid informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following as this regimen may be harmful to a developing fetus or nursing&#xD;
             child:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Breastfeeding women&#xD;
&#xD;
               -  Men or women of childbearing potential or their sexual partners who are unwilling&#xD;
                  to employ adequate contraception (condoms, diaphragm, birth control pills,&#xD;
                  injections, intrauterine device [IUD], surgical sterilization, subcutaneous&#xD;
                  implants, or abstinence, etc.)&#xD;
&#xD;
          -  Any of the following prior therapies:&#xD;
&#xD;
               -  Prior chemotherapy for NSCLC (exception: therapies used as a radiosensitizer such&#xD;
                  as low-dose weekly cisplatin and carbo/taxol with XRT)&#xD;
&#xD;
               -  Prior radiation &gt; 25% of bone marrow&#xD;
&#xD;
               -  Prior immunotherapy, biologic or gene therapy&#xD;
&#xD;
          -  New York Heart Association classification III or IV&#xD;
&#xD;
          -  CNS metastases&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Any other severe, underlying diseases that are, in the judgment of the investigator,&#xD;
             inappropriate for entry into this study&#xD;
&#xD;
          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin&#xD;
             cancer, adequately treated noninvasive carcinomas, or other cancer from which the&#xD;
             patient has been disease-free for at least five years&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy (motor or sensory) &gt; grade 1 per NCI Common&#xD;
             Toxicity Criteria (CTC)&#xD;
&#xD;
          -  Known peripheral vascular disease or a history of deep vein thrombosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Adjei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

